Lupus Clinical GuidancE
The CITE lupus clinical guidance documents provide healthcare professionals with evidence-based recommendations for the diagnosis, assessment, and management of patients with lupus. These guidance documents are developed by an expert panel of clinicians who evaluate the available literature and develop consensus-based recommendations based on the best available evidence.
Lupus is a complex and often unpredictable autoimmune disease that can affect multiple organs and systems in the body. The symptoms and severity of lupus can vary widely from patient to patient, and there is currently no cure for the disease. As a result, clinical guidance documents play an important role in helping healthcare professionals navigate the challenges of diagnosing and treating patients with lupus.
There are currently two CITE lupus clinical guidance documents. The topics are:
-
Lupus Nephritis
-
The Appropriate use of Hydroxychloroquine - COMING SOON
Authors:
Ann Clarke, MD MSc FRCPC
Professor, Division of Rheumatology, Department of Medicine
University of Calgary, Calgary AB
Stephanie Keeling, MD MSc FRCPC
Associate Professor of Medicine in the Division of Rheumatology
University of Alberta, Edmonton AB
Mark Matsos, MD FRCPC
Associate Professor, Division of Rheumatology, Department of Medicine
McMaster University, Hamilton ON
Christine Peschken, MD MSc FRCPC
Professor of Medicine and Community Health Sciences, Rady Faculty of Health Sciences, Head, Section of Rheumatology
University of Manitoba, Winnipeg MB
Zahi Touma, MD PhD FRCPC
Associate Professor of Medicine, University of Toronto
Clinician-Scientist, Rheumatology, University Health Network and Mount Sinai Hospital, Toronto ON
Konstantinos Tselios, MD PhD FRCPC
Assistant Professor, Division of Rheumatology, Department of Medicine
McMaster University, Hamilton ON
Michael Walsh, MD MSc PhD FRCPC
Assistant Professor of Medicine (Nephrology) and Clinical Epidemiology and Biostatistics
McMaster University, Hamilton ON
This initiative has been sponsored in part by GlaxoSmithKline through an educational grant.